Table 1.
Demographics of patients with irAEs.
| Variables | Cohort 1 (n = 152) | Cohort 2 (n = 246) | p-Value | |||
|---|---|---|---|---|---|---|
| n | % | n | % | |||
| Age (mean) | 64.3 | 62.4 | p = 0.255 | |||
| Sex | Female | 59 | 38.8 | 97 | 39.4 | p = 0.903 |
| Male | 93 | 61.2 | 149 | 60.6 | ||
| Race | Asian | 11 | 7.2 | 10 | 4.1 | p = 0.150 |
| Black | 4 | 2.6 | 2 | 0.8 | ||
| Native American | 2 | 1.3 | 0 | 0 | ||
| White | 126 | 82.9 | 221 | 89.8 | ||
| Other | 4 | 2.6 | 4 | 1.7 | ||
| N/A | 5 | 3.3 | 9 | 3.7 | ||
| Ethnicity | Hispanic | 9 | 5.9 | 13 | 5.3 | p = 0.963 |
| Not Hispanic | 137 | 90.1 | 223 | 90.7 | ||
| N/A | 6 | 4.0 | 10 | 4.1 | ||
| Tumor Type | Breast | 1 | 0.7 | 2 | 0.8 | p < 0.001 |
| Cervical | 2 | 1.3 | 2 | 0.8 | ||
| CNS | 3 | 2.0 | 5 | 2.03 | ||
| Colorectal | 5 | 3.3 | 3 | 1.2 | ||
| Endometrial | 10 | 6.6 | 3 | 1.2 | ||
| Gastrointestinal/Hepatobiliary | 9 | 5.9 | 30 | 12.2 | ||
| Genitourinary | 47 | 30.9 | 39 | 15.9 | ||
| Head and Neck/ Endocrine | 4 | 2.6 | 9 | 3.7 | ||
| Hematologic | 0 | 0.0 | 8 | 3.3 | ||
| Lung | 31 | 20.1 | 46 | 18.7 | ||
| Melanoma | 25 | 16.5 | 76 | 30.9 | ||
| Merkel Cell Carcinoma | 4 | 2.6 | 4 | 1.6 | ||
| Ovarian | 2 | 1.3 | 4 | 1.6 | ||
| Prostate | 3 | 2.0 | 14 | 5.7 | ||
| Sarcoma | 6 | 4.0 | 1 | 0.4 | ||
| ICB Type | Atezolizumab (anti-PDL1) | 11 | 7.2 | 9 | 3.7 | p < 0.001 |
| Avelumab (anti-PDL1) | 8 | 5.3 | 2 | 0.8 | ||
| Cemiplimab (anti-PD1) | 0 | 0.0 | 1 | 0.4 | ||
| Durvalumab (anti-PDL1) | 7 | 4.6 | 7 | 2.9 | ||
| Durvalumab (anti-PDL1)/ Tremelimumab (anti-CTLA4) | 0 | 0.0 | 7 | 2.9 | ||
| Ipilimumab (anti-CTLA4) | 0 | 0.0 | 35 | 14.2 | ||
| Ipilimumab (anti-CTLA4)/ Nivolumab (anti-PD1) | 38 | 25.0 | 71 | 28.9 | ||
| Nivolumab (anti-PD1) | 30 | 19.7 | 35 | 14.2 | ||
| Pembrolizumab (anti-PD1) | 58 | 38.2 | 76 | 30.9 | ||
| Tremelimumab (anti-CTLA4) | 0 | 0.0 | 2 | 0.8 | ||
p-values represent t-tests (age) and chi-squared tests (sex, race, ethnicity, tumor type, ICB type) between Cohort 1 and Cohort 2.